^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    atigotatug (BMS-986012)

    i
    Other names: BMS-986012, MDX-1110, BMS986012, MDX1110, BMS 986012, MDX 1110, 7E4
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    Fucosyl GM1 inhibitor
    Associations

    News

    Trials
    over1year
    A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (clinicaltrials.gov)
    P3, N=530, Not yet recruiting, Bristol-Myers Squibb
    New P3 trial • Combination therapy
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)
    over1year
    Trial of BMS-986012 in Combination With Platinum and Etoposide (clinicaltrials.gov)
    P1, N=12, Completed, Bristol-Myers Squibb | Active, not recruiting --> Completed
    Trial completion • Combination therapy
    |
    cisplatin • carboplatin • etoposide IV • atigotatug (BMS-986012)
    over1year
    A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Active, not recruiting, Bristol-Myers Squibb | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)
    almost2years
    A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Bristol-Myers Squibb | Trial completion date: Mar 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Dec 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Opdivo (nivolumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)
    2years
    Trial of BMS-986012 in Combination With Platinum and Etoposide (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Bristol-Myers Squibb | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2023 --> Jun 2024
    Phase classification • Trial completion date • Combination therapy
    |
    cisplatin • carboplatin • etoposide IV • atigotatug (BMS-986012)
    almost4years
    A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Bristol-Myers Squibb | Trial primary completion date: Sep 2023 --> Feb 2024
    Trial primary completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)
    4years
    A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Bristol-Myers Squibb | Trial completion date: Sep 2024 --> Mar 2025
    Trial completion date • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)
    almost5years
    A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, Bristol-Myers Squibb | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)
    5years
    A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Bristol-Myers Squibb
    Clinical • New P2 trial • Combination therapy • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • carboplatin • etoposide IV • atigotatug (BMS-986012)